A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Abemaciclib (Primary) ; Loperamide; Tamoxifen
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms nextMONARCH 1
- Sponsors Eli Lilly
- 11 Apr 2017 Planned End Date changed from 1 Aug 2019 to 1 May 2019.
- 19 Sep 2016 Status changed from not yet recruiting to recruiting.
- 27 Apr 2016 New trial record